- Home
- ECX vs CELC Comparison
ECX vs CELC Comparison
Compare ECX & CELC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ECX
- CELC
- Stock Information
- Founded
- ECX 2017
- CELC 2011
- Country
- ECX China
- CELC United States
- Employees
- ECX N/A
- CELC N/A
- Industry
- ECX EDP Services
- CELC Medical Specialities
- Sector
- ECX Technology
- CELC Health Care
- Exchange
- ECX Nasdaq
- CELC Nasdaq
- Market Cap
- ECX 584.9M
- CELC 489.7M
- IPO Year
- ECX N/A
- CELC 2017
- Fundamental
- Price
- ECX $1.82
- CELC $12.52
- Analyst Decision
- ECX
- CELC Strong Buy
- Analyst Count
- ECX 0
- CELC 6
- Target Price
- ECX N/A
- CELC $29.17
- AVG Volume (30 Days)
- ECX 355.8K
- CELC 232.9K
- Earning Date
- ECX 11-07-2024
- CELC 11-14-2024
- Dividend Yield
- ECX N/A
- CELC N/A
- EPS Growth
- ECX N/A
- CELC N/A
- EPS
- ECX N/A
- CELC N/A
- Revenue
- ECX $778,608,168.00
- CELC N/A
- Revenue This Year
- ECX $20.12
- CELC N/A
- Revenue Next Year
- ECX $32.70
- CELC N/A
- P/E Ratio
- ECX N/A
- CELC N/A
- Revenue Growth
- ECX 25.45
- CELC N/A
- 52 Week Low
- ECX $0.96
- CELC $11.51
- 52 Week High
- ECX $3.44
- CELC $22.19
- Technical
- Relative Strength Index (RSI)
- ECX 46.50
- CELC 38.01
- Support Level
- ECX $1.89
- CELC $11.94
- Resistance Level
- ECX $2.02
- CELC $13.14
- Average True Range (ATR)
- ECX 0.11
- CELC 0.50
- MACD
- ECX -0.00
- CELC 0.05
- Stochastic Oscillator
- ECX 8.33
- CELC 37.68
About ECX ECARX Holdings Inc. Ordinary shares
ECARX Holdings Inc is engaged in the sales of system-on-chip core modules, automotive computing platform products, and software stacks as well as the provision of research and development services primarily in the People's Republic of China. The company's core products include infotainment head units, digital cockpits, vehicle chip-set solutions, a core operating system, and an integrated software stack. Beyond this, ECARX is developing a full-stack automotive computing platform. It is engaged in automotive intelligence and networking.
About CELC Celcuity Inc.
Celcuity Inc is a clinical-stage biotechnology company pursuing development for oncology. The Company's lead therapeutic candidate is gedatolisib, a potent pan-PI3K and mTOR inhibitor. Its mechanism of action and pharmacokinetic properties are highly differentiated from other currently approved and investigational therapies that target PI3K or mTOR alone or together. A Phase 3 clinical trial, VIKTORIA-1, evaluating gedatolisib in combination with fulvestrant with or without palbociclib in patients with HR+/HER2- advanced breast cancer is currently enrolling patients.